Clinical outcomes after conversion from brand-name tacrolimus (Prograf) to a generic formulation in renal transplant recipients: A retrospective cohort study

P and T

Volumn 38, Issue 8, 2013, Pages 484-488

  Marfo, Kwaku ^a   Aitken, Samuel ^b   Akalin, Enver ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; BACTEREMIA; CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; DRUG FORMULATION; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; PNEUMONIA; RETROSPECTIVE STUDY; URINARY TRACT INFECTION;

EID: 84882596047     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. KDIGO [Kidney Disease: Improving Global Outcomes] clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009(9 Suppl 3):S1-S155.
2. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997;64:436-443.
3. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analysis of randomised trials. BMJ 1999;318:1104-1107.
4. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-430.
5. Nightingale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA 1987;258:1200-1204.
6. Facts at a Glance. About GPhA. Washington, D.C.: Generic Pharmaceutical Association, 2010. Available at: gpha. hfwebdev. com/about-gpha/about-generics/facts. Accessed May 23, 2013.
7. Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: Evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res 2003;38:1051-1063.
8. Haas JS, Phillips KA, Gerstenberger EP, et al. Potential savings from substituting generic drugs for brand-name drugs: Medical expenditure panel survey, 1997-2000. Ann Intern Med 2005;142:891-897.
9. FDA, Center for Drug Evaluation and Research. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. January 2001. Available at: www.fda.gov/downloads/Drugs/ Guidances/ucm070244.pdf. Accessed April 3, 2013.
10. Davit BM, Nwakama PE, Buehler GI. Comparing generic and innovator drugs: A review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009;43:1583-1597.
11. Taber DJ, Baillie GM, Ashcraft EE, et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 2005;80:1633-1635.
12. Qazi YA, Forrest A, Tornatore K, et al. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant 2006;20:313-317.
13. Carnahan W, Cooper TY. Neoral-to-Gengraf conversion in renal transplant recipients. Transplant Proc 2003;35:1308-1313.
14. Sabatini S, Ferguson RM, Helderman JH, et al. Drug substitution in transplantation: A National Kidney Foundation white paper. Am J Kidney Dis 1999;33:389-397.
15. Muller H, Solari S, Zuniga C, et al. Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: Preliminary report in Chile. Transplant Proc 2008;40:705-707.
16. Guleria S, Kamboj M, Chatterjee A, et al. Generic tacrolimus (Pan Graf) in renal transplantation: An experience of 155 recipients in India. Transplant Proc 2008;40:2237-2239.
17. Momper JD, Ridenour TA, Schonder KS, et al. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 2011;11:1861-1867.
18. McDevitt-Potter LM, Sadaka B, Tichy EM, et al. A multicenter experience with generic tacrolimus conversion. Transplantation 2011;92:653-657.
19. Orange Book: Approved Drug Products with Therapeutic Equivalence Equations. Current through April 2013, updated May 17, 2013. Available at: www.accessdata.fda.gov/scripts/cder/ob/docs/ default.cfm. Accessed June 3, 2013.
20. Spence MM, Nguyen LM, Hui RL, Chan J. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy 2012;32(11):981-987.
21. Alloway RR, Sadaka B, Trofe-Clark J, et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 2012;12:2825-2831.